← Back to all trials
Recruiting
NCT07654140
A Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Uncontrolled Hypertension
Conditions: Uncontrolled Hypertension
Sex: All
Ages: 18 Years – 75 Years
Healthy volunteers: No
Phase: PHASE2
Enrollment: 252
Sponsor: Shenzhen Salubris Pharmaceuticals Co., Ltd.
Location: Beijing Anzhen Hospital Capital Medical University Beijing Beijing Municipality
Summary
This is a multicenter, randomized, double-blind, placebo-controlled phase II study designed to explore the efficacy and safety of different doses of SAL0140 in uncontrolled hypertension.
Eligibility Criteria
Inclusion Criteria:
1. Patients 18-75 years old, male or female.
2. Mean seated systolic blood pressure (msSBP) at screening was ≥140 mmHg and \
Source: ClinicalTrials.gov (NCT07654140). StuddyBuddy aggregates publicly available trial information.
